GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edesa Biotech Inc (NAS:EDSA) » Definitions » Cyclically Adjusted PB Ratio

Edesa Biotech (Edesa Biotech) Cyclically Adjusted PB Ratio : 0.03 (As of May. 24, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Edesa Biotech Cyclically Adjusted PB Ratio?

As of today (2024-05-24), Edesa Biotech's current share price is $4.465. Edesa Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $157.49. Edesa Biotech's Cyclically Adjusted PB Ratio for today is 0.03.

The historical rank and industry rank for Edesa Biotech's Cyclically Adjusted PB Ratio or its related term are showing as below:

EDSA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.02   Med: 0.12   Max: 0.34
Current: 0.03

During the past years, Edesa Biotech's highest Cyclically Adjusted PB Ratio was 0.34. The lowest was 0.02. And the median was 0.12.

EDSA's Cyclically Adjusted PB Ratio is ranked better than
95.09% of 652 companies
in the Biotechnology industry
Industry Median: 1.74 vs EDSA: 0.03

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Edesa Biotech's adjusted book value per share data for the three months ended in Mar. 2024 was $1.345. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $157.49 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Edesa Biotech Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Edesa Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edesa Biotech Cyclically Adjusted PB Ratio Chart

Edesa Biotech Annual Data
Trend Aug14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.28 0.31 0.04 0.02

Edesa Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.03 0.02 0.03 0.03

Competitive Comparison of Edesa Biotech's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Edesa Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edesa Biotech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's Cyclically Adjusted PB Ratio falls into.



Edesa Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Edesa Biotech's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.465/157.49
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Edesa Biotech's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.345/126.2576*126.2576
=1.345

Current CPI (Mar. 2024) = 126.2576.

Edesa Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201405 419.759 99.394 533.207
201408 289.294 99.315 367.774
201412 341.353 98.367 438.138
201503 329.749 99.789 417.212
201506 348.596 100.500 437.938
201509 294.735 100.421 370.564
201512 335.108 99.947 423.322
201603 306.646 101.054 383.128
201606 266.562 102.002 329.950
201609 357.135 101.765 443.091
201612 315.110 101.449 392.170
201703 283.933 102.634 349.288
201706 240.274 103.029 294.446
201709 206.792 103.345 252.641
201712 168.222 103.345 205.519
201803 132.476 105.004 159.290
201806 97.597 105.557 116.737
201809 88.930 105.636 106.290
201812 78.065 105.399 93.514
201903 65.159 106.979 76.901
201906 5.795 107.690 6.794
201909 4.903 107.611 5.753
201912 3.949 107.769 4.626
202003 5.476 107.927 6.406
202006 4.220 108.401 4.915
202009 4.827 108.164 5.634
202012 5.245 108.559 6.100
202103 10.185 110.298 11.659
202106 8.346 111.720 9.432
202109 6.875 112.905 7.688
202112 5.462 113.774 6.061
202203 7.707 117.646 8.271
202206 5.359 120.806 5.601
202209 3.945 120.648 4.128
202212 3.716 120.964 3.879
202303 3.141 122.702 3.232
202306 2.633 124.203 2.677
202309 2.292 125.230 2.311
202312 1.847 125.072 1.865
202403 1.345 126.258 1.345

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Edesa Biotech  (NAS:EDSA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Edesa Biotech Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Edesa Biotech's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Edesa Biotech (Edesa Biotech) Business Description

Traded in Other Exchanges
N/A
Address
100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
Executives
Stephen Lemieux officer: Chief Financial Officer 100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6
Joan Chypyha director 100 SPY COURT, MARKHAM A6 L3R 5H6
Patrick Marshall director 100 SPY COURT, MARKHAM A6 L3R 5H6
Van Der Velden Peter director, 10 percent owner C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Michael J Brooks officer: President C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Pardeep Nijhawan director, 10 percent owner, officer: Chief Executive Officer C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
Frank R. Oakes director, officer: President, CEO, & Director C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041
Sean Arthur Macdonald director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lorin K Johnson director 3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303
Pardeep Nijhawan Medicine Professional Corp 10 percent owner C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Paul William Pay director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Carlo Sistilli director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lumira Capital Investment Management Inc. 10 percent owner 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Daniel E. Morse director C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041